Loading...
Antibe Therapeutics Inc.
ATBPF•PNK
Healthcare
Medical - Devices
$0.22
$-0.00(-0.19%)

Over the last four quarters, Antibe Therapeutics Inc. achieved steady financial progress, growing revenue from $0.00 in Q1 2023 to $0.00 in Q4 2023. Gross profit stayed firm with margins at N/A in Q4 2023 versus N/A in Q1 2023. Operating income totaled -$3.58M in Q4 2023, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$3.23M. Net income rose to -$3.55M, with EPS at -$0.07. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan